CR20130593A - Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b - Google Patents

Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b

Info

Publication number
CR20130593A
CR20130593A CR20130593A CR20130593A CR20130593A CR 20130593 A CR20130593 A CR 20130593A CR 20130593 A CR20130593 A CR 20130593A CR 20130593 A CR20130593 A CR 20130593A CR 20130593 A CR20130593 A CR 20130593A
Authority
CR
Costa Rica
Prior art keywords
maitansinoid
symptom
tumors
immunocated
antibody
Prior art date
Application number
CR20130593A
Other languages
English (en)
Inventor
Rodica Morariu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130593(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20130593A publication Critical patent/CR20130593A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se utiliza un inmunoconjugado de maitansinoide anti-CD19 para tratar el síntoma tumores de células B CD19, en particular el linfoma no-Hodgkin.
CR20130593A 2011-05-17 2013-11-13 Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b CR20130593A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11290232A EP2524929A1 (en) 2011-05-17 2011-05-17 Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms

Publications (1)

Publication Number Publication Date
CR20130593A true CR20130593A (es) 2014-01-09

Family

ID=46085972

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130593A CR20130593A (es) 2011-05-17 2013-11-13 Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b

Country Status (30)

Country Link
US (2) US9555126B2 (es)
EP (2) EP2524929A1 (es)
JP (4) JP6050328B2 (es)
KR (1) KR20140043388A (es)
CN (2) CN107007840A (es)
AR (1) AR086412A1 (es)
AU (3) AU2012258254B2 (es)
BR (1) BR112013029330A8 (es)
CA (1) CA2835738A1 (es)
CL (1) CL2013003272A1 (es)
CO (1) CO6821893A2 (es)
CR (1) CR20130593A (es)
DO (1) DOP2013000260A (es)
EA (1) EA028574B1 (es)
EC (1) ECSP13013084A (es)
GT (1) GT201300276A (es)
IL (3) IL229380B (es)
MA (1) MA35180B1 (es)
MX (1) MX347019B (es)
MY (1) MY163736A (es)
NI (1) NI201300119A (es)
PE (1) PE20141018A1 (es)
PH (1) PH12017501368A1 (es)
SG (2) SG194894A1 (es)
TN (1) TN2013000468A1 (es)
TW (3) TW201726167A (es)
UA (1) UA114401C2 (es)
UY (1) UY34077A (es)
WO (1) WO2012156455A1 (es)
ZA (1) ZA201309400B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
SG10201907501QA (en) 2013-08-30 2019-10-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
CN105837689B (zh) * 2015-01-13 2020-06-19 博生吉安科细胞技术有限公司 抗cd19单克隆抗体及其制备方法
WO2016180941A1 (en) * 2015-05-13 2016-11-17 Sanofi Liquid compositions for anti-cd19 antibody-drug conjugates
US10617691B2 (en) 2015-05-26 2020-04-14 Morphosys Ag Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
EP4335851A3 (en) 2015-11-25 2024-06-05 ImmunoGen, Inc. Pharmaceutical formulations and methods of use thereof
ES2981046T3 (es) 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
CN115998859A (zh) 2016-06-27 2023-04-25 莫佛塞斯公司 抗-cd19抗体制剂
MX2019004942A (es) 2016-10-28 2019-08-12 Morphosys Ag Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
US20200405879A1 (en) * 2017-04-20 2020-12-31 Adc Therapeutics Sa Combination therapy
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
KR20200055758A (ko) * 2017-09-21 2020-05-21 우시 바이올로직스 아일랜드 리미티드 신규 항-cd19 항체
JP7474195B2 (ja) 2018-01-12 2024-04-24 イミュノジェン， インコーポレイテッド 抗体薬物のコンジュゲーション、精製、及び製剤のための方法
CN113766954B (zh) 2019-04-26 2024-09-24 伊缪诺金公司 喜树碱衍生物
SG11202111343TA (en) 2019-05-03 2021-11-29 Morphosys Ag Anti-cd19 therapy in patients having a limited number of nk cells
IL292181A (en) 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
AU2020372646A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells
AU2020374947A1 (en) * 2019-10-31 2022-03-31 Forty Seven, Inc. Anti-CD47 and anti-CD20 based treatment of blood cancer
CN110845617B (zh) * 2019-12-05 2021-07-09 常州费洛斯药业科技有限公司 针对cd19的全人源抗体或抗体片段、嵌合抗原受体及应用
CA3181827A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
MX2023003997A (es) 2020-10-06 2023-06-15 Xencor Inc Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les).
WO2022117799A2 (en) 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
DK1651162T3 (en) 2003-05-20 2016-02-01 Immunogen Inc IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS
RU2495882C2 (ru) * 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
SG173152A1 (en) * 2009-02-05 2011-08-29 Immunogen Inc Novel benzodiazepine derivatives
RU2561041C2 (ru) * 2009-05-06 2015-08-20 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
CA2775806A1 (en) * 2009-10-21 2011-04-28 Immunogen, Inc. Novel dosing regimen and method of treatment
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab

Also Published As

Publication number Publication date
SG10201609729VA (en) 2016-12-29
JP2014515036A (ja) 2014-06-26
PE20141018A1 (es) 2014-08-27
AU2012258254B2 (en) 2016-04-21
JP6050328B2 (ja) 2016-12-21
US20170196988A1 (en) 2017-07-13
BR112013029330A8 (pt) 2018-01-30
CL2013003272A1 (es) 2014-08-01
US20140072587A1 (en) 2014-03-13
EP2710034A1 (en) 2014-03-26
CA2835738A1 (en) 2012-11-22
DOP2013000260A (es) 2014-01-31
CN107007840A (zh) 2017-08-04
AU2016206317A1 (en) 2016-08-11
AU2018201504A1 (en) 2018-03-22
TW201834687A (zh) 2018-10-01
BR112013029330A2 (pt) 2016-11-29
AU2012258254A1 (en) 2013-05-02
MA35180B1 (fr) 2014-06-02
TWI601537B (zh) 2017-10-11
JP6181273B2 (ja) 2017-08-16
US9555126B2 (en) 2017-01-31
NZ618012A (en) 2016-03-31
KR20140043388A (ko) 2014-04-09
MX347019B (es) 2017-04-07
AR086412A1 (es) 2013-12-11
JP2017081926A (ja) 2017-05-18
EP2524929A1 (en) 2012-11-21
TW201726167A (zh) 2017-08-01
WO2012156455A1 (en) 2012-11-22
CN103547596A (zh) 2014-01-29
IL263728A (en) 2019-01-31
GT201300276A (es) 2015-03-23
PH12017501368A1 (en) 2018-01-29
IL229380B (en) 2018-02-28
UY34077A (es) 2013-01-03
MX2013013455A (es) 2014-02-17
SG194894A1 (en) 2013-12-30
UA114401C2 (uk) 2017-06-12
JP2019142961A (ja) 2019-08-29
EA201391714A1 (ru) 2014-03-31
CO6821893A2 (es) 2013-12-31
IL257475A (en) 2018-06-28
EA028574B1 (ru) 2017-12-29
TN2013000468A1 (en) 2015-03-30
IL229380A0 (en) 2014-01-30
NI201300119A (es) 2014-02-28
JP2018021020A (ja) 2018-02-08
ECSP13013084A (es) 2014-01-31
ZA201309400B (en) 2015-04-29
TW201249460A (en) 2012-12-16
MY163736A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
ECSP13013084A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CU20170023A7 (es) Anticuerpos y receptores de antígeno quiméricos específicos para cd19
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
CR20140406A (es) Anticuerpos cd47 y métodos de uso de los mismos
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
UY34230A (es) Terapia de combinación para tumores malignos de células b cd19+ que comprende un inmunoconjugado maitansinoide anti-cd19 y rituximab
MX2015016963A (es) Metodos y composiciones para reducir la inmunosupresion por celulas de tumor.
NZ731782A (en) Pyrrolobenzodiazepine-antibody conjugates
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
UY33647A (es) ?agentes de unión a cd33?.
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CL2012003385A1 (es) Tratamiento para la incontinencia.
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
EA201400178A1 (ru) Лечение рака молочной железы
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
CL2013000238A1 (es) Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
BR112012018021A2 (pt) antídotos anticoagulantes.
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
TR201911039T4 (tr) Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler.
EA201400447A1 (ru) АНТИТЕЛА К CD1d
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
BR112015013260A2 (pt) uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas